Thrivent Financial for Lutherans Acquires New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Thrivent Financial for Lutherans purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 104,764 shares of the biopharmaceutical company's stock, valued at approximately $2,450,000. Thrivent Financial for Lutherans owned 0.07% of TG Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares in the last quarter. Quarry LP grew its stake in TG Therapeutics by 9.1% during the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 503 shares during the period. Private Advisor Group LLC increased its holdings in TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company's stock worth $337,000 after purchasing an additional 542 shares in the last quarter. Blue Trust Inc. lifted its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after buying an additional 849 shares during the period. Finally, KBC Group NV boosted its holdings in shares of TG Therapeutics by 30.5% during the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company's stock worth $109,000 after buying an additional 1,092 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TGTX has been the subject of several research analyst reports. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday. TD Cowen began coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 price target on the stock. B. Riley boosted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Finally, HC Wainwright increased their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

Insiders Place Their Bets

In related news, Director Sagar Lonial sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company's stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.50% of the company's stock.

TG Therapeutics Stock Up 2.2 %

TGTX traded up $0.74 during mid-day trading on Thursday, reaching $35.00. 1,680,767 shares of the stock were exchanged, compared to its average volume of 3,686,240. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a 50 day moving average price of $26.19 and a two-hundred day moving average price of $22.04. TG Therapeutics, Inc. has a 1 year low of $12.32 and a 1 year high of $36.84. The stock has a market capitalization of $5.45 billion, a PE ratio of -349.97 and a beta of 2.19.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same quarter last year, the business posted $0.73 earnings per share. The business's revenue was down 49.4% compared to the same quarter last year. As a group, research analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.